{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T03:01:02Z","timestamp":1780282862447,"version":"3.54.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["Biogen"],"award-info":[{"award-number":["Biogen"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Friedreich ataxia (FA) is a hereditary degenerative disease with clinical manifestations in multiple organs characterized by progressive gait and limb ataxia. Qualitative interviews were conducted with patients and caregivers to characterize the burden experienced related to FA symptoms and impacts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>A sample of 20 FA patients and 11 caregivers were recruited from the Friedreich Ataxia Research Alliance (FARA) registry and FA Facebook communities. Individual qualitative interviews were conducted via telephone by trained qualitative research interviewers to last no more than 45\u00a0min. Audio files were transcribed and coded to group concepts by similarity of theme or concept using ATLAS.ti software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 20 patients interviewed ranged from 22 to 36 years of age (mean 28.45), 75% were female and seven (35%) were still working full-time. The participants interviewed required an average of 55.5\u00a0h per week of assistance from a caregiver. The most frequently reported symptoms were neurological including impaired speech (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914; 70%), loss of balance (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910; 50%) and decreased muscle coordination (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098; 40%). Negative impacts of symptoms included limited function in activities of daily living such as walking (n=15; 75%), dressing (n=11; 55%), limited social activities (n=11; 55%), personal care and hygiene (n=8; 40%), and falls (n=6; 30%). Additionally, 91% of caregivers reported observing falls, and 73% reported issues with patient personal care and hygiene. Patients rated their symptom bothersomeness at 6.7, impact of FA on their ability to live their daily lives at 7.1, and their financial burden due to FA at 6.5, all on a 9-point scale where higher scores indicate worse outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results show that from both the patient and caregiver perspective living with FA is highly burdensome for patients, negatively impacting their daily lives, and limiting their ability to lead a functional life, in areas like mobility, self-care, and productivity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-01067-4","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:54:10Z","timestamp":1776513250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring US patient and caregiver perspectives on burden associated with Friedreich Ataxia"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8798-1013","authenticated-orcid":false,"given":"Richard","family":"Lawson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobhana","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia R.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M.","family":"Bushnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Setyawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"5","key":"1067_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2217\/nmt-2022-0011","volume":"12","author":"M Keita","year":"2022","unstructured":"Keita M, McIntyre K, Rodden LN, Schadt K, Lynch DR (2022) Friedreich ataxia: clinical features and new developments. Neurodegener Dis Manag 12(5):267\u2013283. https:\/\/doi.org\/10.2217\/nmt-2022-0011","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"1067_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmg.37.1.1","volume":"37","author":"MB Delatycki","year":"2000","unstructured":"Delatycki MB, Williamson R, Forrest SM (2000) Friedreich ataxia: an overview. J Med Genet 37(1):1\u20138. https:\/\/doi.org\/10.1136\/jmg.37.1.1","journal-title":"J Med Genet"},{"key":"1067_CR3","doi-asserted-by":"publisher","unstructured":"Ocana-Santero G, Diaz-Nido J, Herranz-Martin S (2021) Future prospects of gene therapy for Friedreich\u2019s ataxia. Int J Mol Sci 22(4). https:\/\/doi.org\/10.3390\/ijms22041815","DOI":"10.3390\/ijms22041815"},{"key":"1067_CR4","doi-asserted-by":"crossref","unstructured":"Pandolfo M (2025) Chapter 6 - Friedreich ataxia. In: Rosenberg RN, Pascual JM (eds) Rosenberg\u2019s molecular and genetic basis of neurological and psychiatric disease. Seventh Edition. Academic, pp 107\u2013125","DOI":"10.1016\/B978-0-443-19176-3.00041-8"},{"key":"1067_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.12688\/amrcopenres.13036.1","volume":"3","author":"A Lowit","year":"2021","unstructured":"Lowit A, Greenfield J, Cutting E, Wallis R, Hadjivassiliou M (2021) Symptom burden of people with progressive ataxia, and its wider impact on their friends and relatives: a cross-sectional study. AMRC Open Res 3:28. https:\/\/doi.org\/10.12688\/amrcopenres.13036.1","journal-title":"AMRC Open Res"},{"key":"1067_CR6","unstructured":"Food and Drug Administration FDA approves first treatment for Friedreich\u2019s ataxia. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-treatment-friedreichs-ataxia#:~:text=FDA%20has%20approved%20Skyclarys%20(omaveloxolone,by%20impaired%20coordination%20and%20walking (2023). Accessed March 19 2025"},{"issue":"5","key":"1067_CR7","doi-asserted-by":"publisher","first-page":"e200180","DOI":"10.1212\/CPJ.0000000000200180","volume":"13","author":"J Seabury","year":"2023","unstructured":"Seabury J, Rosero S, Varma A, Weinstein J, Engebrecht C, Dilek N et al (2023) Friedreich\u2019s Ataxia-Health Index: Development and Validation of a Novel Disease-Specific Patient-Reported Outcome Measure. Neurol Clin Pract 13(5):e200180. https:\/\/doi.org\/10.1212\/CPJ.0000000000200180","journal-title":"Neurol Clin Pract"},{"issue":"7","key":"1067_CR8","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1212\/01.WNL.0000156802.15466.79","volume":"64","author":"SH Subramony","year":"2005","unstructured":"Subramony SH, May W, Lynch D, Gomez C, Fischbeck K, Hallett M et al (2005) Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale. Neurology 64(7):1261\u20131262. https:\/\/doi.org\/10.1212\/01.WNL.0000156802.15466.79","journal-title":"Neurology"},{"key":"1067_CR9","unstructured":"Friese S (2013) User\u2019s Manual for ATLAS.ti 7.1.0. https:\/\/atlasti.com\/manuals-and-documents Accessed March 19 2025"},{"issue":"8","key":"1067_CR10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L (2011) Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2013eliciting concepts for a new PRO instrument. Value Health 14(8):967\u2013977. https:\/\/doi.org\/10.1016\/j.jval.2011.06.014","journal-title":"Value Health"},{"issue":"5","key":"1067_CR11","doi-asserted-by":"publisher","first-page":"e0232076","DOI":"10.1371\/journal.pone.0232076","volume":"15","author":"G Guest","year":"2020","unstructured":"Guest G, Namey E, Chen M (2020) A simple method to assess and report thematic saturation in qualitative research. PLoS ONE 15(5):e0232076. https:\/\/doi.org\/10.1371\/journal.pone.0232076","journal-title":"PLoS ONE"},{"key":"1067_CR12","doi-asserted-by":"crossref","unstructured":"Janssen B, Szende A (2013) Population Norms for the EQ-5D. In: Szende A, Janssen B, Cabases J (eds) Self-Reported Population Health: an international perspective based on EQ-5D. Springer","DOI":"10.1007\/978-94-007-7596-1_3"},{"issue":"3","key":"1067_CR13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/hex.12046","volume":"18","author":"A Sav","year":"2015","unstructured":"Sav A, King MA, Whitty JA, Kendall E, McMillan SS, Kelly F et al (2015) Burden of treatment for chronic illness: a concept analysis and review of the literature. Health Expect 18(3):312\u2013324. https:\/\/doi.org\/10.1111\/hex.12046","journal-title":"Health Expect"},{"issue":"1","key":"1067_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s13023-024-03319-2","volume":"19","author":"C Phillips","year":"2024","unstructured":"Phillips C, Parkinson A, Namsrai T, Chalmers A, Dews C, Gregory D et al (2024) Time to diagnosis for a rare disease: managing medical uncertainty. A qualitative study. Orphanet J Rare Dis 19(1):297. https:\/\/doi.org\/10.1186\/s13023-024-03319-2","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"1067_CR15","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1212\/WNL.0000000000201598","volume":"100","author":"J Seabury","year":"2023","unstructured":"Seabury J, Alexandrou D, Dilek N, Cohen B, Heatwole J, Larkindale J et al (2023) Patient-Reported Impact of Symptoms in Friedreich Ataxia. Neurology 100(8):e808\u2013e21. https:\/\/doi.org\/10.1212\/WNL.0000000000201598","journal-title":"Neurology"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01067-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01067-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01067-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T02:20:38Z","timestamp":1780280438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01067-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01067-4","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for this study was obtained from a US ethical, central institutional review board (IRB), in accordance with local law.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RL and SN are current employees of Biogen and may hold Biogen stock.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}